مباشر
Endpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsEndpoints News#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetesClinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer PreventionClinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to DementiaEndpoints NewsIn Washington, biotech's China hawks are winning the conversationClinical OMICsUniversal Coronavirus Vaccine Could Provide Protection Against Future StrainsEndpoints NewsIndustry seeks more clarity on commissioner's voucher programBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 4, 2026BioWorldBioWorld and Nasdaq stock indicesEndpoints NewsHouse committee directs FDA to speed up IND sign-off process
FierceBiotech ٢٥ فبراير ٢٠٢٦

After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst

After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.